If you have trouble reading this newsletter, view the web version here

Home Programme Meeting Info


We are delighted to announce that the Ovarian Club XI Meeting will take place on November 1-3, 2018 in Paris, France.

Following the success of last year’s joint collaboration between the Ovarian Club Meeting (OC) and the Congress on Controversies in Preconception, Preimplantation and Prenatal Genetic Diagnosis (CoGEN), the OC Meeting and CoGEN Congress will take place in concurrently this year as well. Read more >

We look forward to welcoming you in Paris for a new and exciting Ovarian Club experience.

Sincerely yours,

Zeev Shoham
On Behalf of the Ovarian Club XI Organizing Committee
until September 5, 2018




Thursday, November 1, 2018
Fertility preservation hands-on workshop
Director: Dror Meirow
Preregistration needed
17:30-19:00 Welcome reception
Friday, November 2, 2018
08:30-10:00 Session 1: On the forefront of human oocyte biology: aging, bioenergetics, and epigenetics
08:30-09:00 Much more than the spindle: a new perspective on cytoplasmic maturation
David Albertini, USA
09:00-09:30 Comparative biology of oocyte aging
Pierre Comizzoli, USA
09:30-10:00 Testing the potential of in vitro grown oocytes
Helen Picton, UK
10:00-10:30 Primordial follicle recruitment and saving ovarian reserve
Sherman Silber, USA
10:30 -11:00 Coffee break
11:00-13:00 Session 2: Gamete reconstruction
11:00-11:30 Drug-free IVA as an infertility treatment for aging poor responders
Kazuhiro Kawamura, Japan
11:30-12:00 Genome editing reveals a role for OCT4 in human embryogenesis
Alan Handyside, UK
12:00-12:30 Direct gamete differentiation from somatic cells?
Pasqualino Loi, Italy
12:30-13:00 Gamete reconstitution in vitro
13:00-14:00 Lunch Break
14:00-15:00 Session 3: DNA recombination during early embryo development
14:00-14:30 Impact of assisted reproduction on genomic imprinting
Mellissa Mann, USA
14:30-15:00 Advances in understanding the mechanisms regulating human oocyte activation and growth
Helen Picton, UK
15:00-16:00 Session 4: Controlled ovarian hyperstimulation: new drugs, new technologies for whom?
15:00-16:00 New forms of drugs: 1. Long-acting FSH, 2. FSH biosimilars and the new recombinant FSH, 3. Progesterone support: I.M., S.C., vaginal and oral
New protocols: 1. Minimal number of injections protocol, 2. Progesterone use to block LH surge. No routine antagonist, 3. Flexibility in starting ovarian stimulation, 4. Double ovarian stimulation
Norbert Gleicher, USA
16:00-16:30 Coffee break
16:30-18:00 Session 5: Debate: The use of CRISPR/Cas9 technology in human embryos
16:30-17:00 Introduction: CRISPR/Cas9
Gerald Schatten, USA
17:00-17:30 For: CRISPR/Cas9
17:30-18:00 Ethics: CRISPR/Cas9 and the ban on human germline editing
Saturday, November 3, 2018
08:30-10:30 Session 6: Implantation, luteal support and tissue cryopreservation (Part 1)
08:30-09:00 How do we choose the best progesterone to support the luteal phase?
Herman Tournaye, Belgium
09:00-09:30 Chronic endometritis and endometriosis: how these two combine for altering endometrial receptivity
09:30-10:00 Freeze-dry: are we reaching the clinical stage?
Amir Arav, Israel
10:00-10:30 Four simple minimum rules to follow for generating a mammalian blastocyst
10:30 -11:00 Coffee break
11:00-13:00 Session 7: Implantation, luteal support and tissue cryopreservation (Part 2)
11:00-11:30 Human immature oocytes can be grown to maturity in vitro: next steps towards clinical application
Evelyn Telfer, UK
11:30-12:00 Single center success in freezing ovarian tissue: How we overcome the various obstacles
12:00-12:30 A critical review of ovarian tissue freezing
Jacques Donnez, Belgium
12:30-13:00 First clinical results of capacitation culture preceding in vitro maturation of human oocytes from small antral follicles in PCOS
Johan Smitz, Belgium
13:00-14:00 Lunch break
14:00-16:00 Session 8: 40 years of IVF: Best practices with respect to outcome, based on accumulated outcome results
14:00-14:30 Managing young women approaching menopause, with high FSH and low AMH
Norbert Gleicher, USA
14:30-16:00 Open discussion on:
  • Insemination parameters (The minimum number is based on what parameters?)
  • DAY 2,3,4,5,6 transfer
  • Best embryo culture systems
  • Time-lapse vs. timed-static imaging
  • When is PGS truly needed and in which cases does PGS clearly improve outcomes?
  • All ICSI vs. conventional IVF: why and when?
16:00-16:30 Coffee break
16:30-18:30 Session 9: The embryo
16:30-17:00 Hormonal regulation of embryo transport
Kenneth Korach, USA
17:00-17:30 Nuclear transfer: Clinical applications
17:30-18:00 New challenges of mitochondria research in ART
Chii Ruey Tzeng, Taiwan
18:00-18:30 Nucleic acids and embryo viability
Samir Hamamah, France


Learn more


Learn more


Click here


oc2018.cme-congresses.com  |  oc@cme-congresses.com

© 2018 CME-Congresses. All Rights Reserved.

Icon credits

If you prefer not to receive future email communications from us, please unsubscribe here

This newsletter was sent using ITnewsletter